Niacin and Endothelial Function in Early CKD

Completed · Phase 4 · Has a placebo group

Conditions studied: Chronic Kidney Disease

In brief

The purpose of this study is to obtain information on whether raising levels of HDL-cholesterol (the "good" cholesterol) can improve how blood vessels work in kidney disease. This may help us understand the causes leading to high rates of heart disease in kidney disease and also ways to reduce this risk.

Key facts

Study ID

NCT00852969

Run by

Tufts Medical Center

People needed

30

Starts

2008-08-01

Expected to finish

2012-04-01

Last updated by the study team

2014-05-06

Who can join

Age: 21 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of CKD Stage 2 (GFR >60 and microalbuminuria/proteinuria) and Stage 3-4 (GFR 15-30)
• HDL-cholesterol <50 for men and <55 for women
• If taking a statin, stable dose for past one month
• Glucose <200 mg/dL and HbA1c <9%
• Transplant recipients who are in stage 2-3 CKD; 1-year post transplant; and have had no rejection episodes in the 6-months prior to study entry

You may not qualify if…

• Hospitalization within prior 3 months
• Any of the following conditions:
• uncontrolled peptic ulcer disease
• active liver disease OR abnormal SGOT/SGPT
• history of adverse reaction to niacin
• contra-indication to aspirin
• concurrent fibrate therapy
• history of gout
• serum phosphorus levels below 2.7mg/dl
• Nursing
• Pregnancy

Where it is running

• Tufts Medical Center — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.